Evidence map›Paper›PMID 31563503›Full record

ArticleEuropean urology2020

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, Gottfrid Sjödahl, A Gordon Robertson, Roland Seiler, Katherine A Hoadley, Clarice S Groeneveld, Hikmat Al-Ahmadie, Woonyoung Choi and 21 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 794 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
794citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

794 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. SEOM-SOGUG clinical guideline for urothelial cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

734 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Aurélie KamounCartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France. Electronic address: aurelie.kamoun@ponts.org.
Aurélien de ReynièsCartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France.
Yves AlloryDepartment of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Gottfrid SjödahlDivision of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
A Gordon RobertsonCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC, Canada.
Roland SeilerDepartment of Urology, Bern University Hospital, Bern, Switzerland.
Katherine A HoadleyDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Clarice S GroeneveldCartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil.
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Woonyoung ChoiJohns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Mauro A A CastroBioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil.
Jacqueline FontugneDepartment of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Pontus ErikssonDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Qianxing MoDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jordan KardosDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alexandre ZlottaDivision of Urology, Department of Surgery, University of Toronto, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada.
Arndt HartmannInstitute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
Colin P DinneyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joaquim BellmuntBladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Thomas PowlesBarts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK.
Núria MalatsGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
Keith S ChanCedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA.
William Y KimDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David J McConkeyJohns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Lars DyrskjøtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Mattias HöglundDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Seth P LernerScott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Francisco X RealEpithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
François RadvanyiInstitut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Bladder Cancer Molecular Taxonomy Group

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

backgroundMuscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application.

objectiveTo achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. DESIGN, SETTING, AND

participantsWe used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. RESULTS AND LIMITATIONS: We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment.

conclusionsThis consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. PATIENT SUMMARY: Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting.

Indexed as

AgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesUrinary Bladder NeoplasmsConsensusMolecular taxonomyMuscle-invasive bladder cancerTranscriptomic classifier

Identifiers

PMID31563503
PMCPMC7690647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.